FDA Warns Of Possible Birth Defects From Dolutegravir HIV Drug
The FDA said the neural tube defects involve the brain, spine and spinal cord.
The agency said the defects were reported in babies born to women treated with dolutegravir for the mother’s HIV infection. The FDA said the preliminary results are from an observational study...
To view the full article, register now.